<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>

<channel>
	<title>Audio Medica - Medical Audio News Interviews &#038; Podcasts &#187; San Antonio BC 2005</title>
	<atom:link href="http://www.audiomedica.com/category/oncology/san-antonio-bc-2005/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.audiomedica.com</link>
	<description>Audio Medica brings informally spoken comments from the world's most significant medical experts.</description>
	<pubDate>Tue, 11 Nov 2008 23:49:38 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.6</generator>
	<language>en</language>
			<item>
		<title>Non-Anthracyline Regimen May Be O.K. for Patients with Early Breast Cancer taking Trastuzumab (Herceptin)</title>
		<link>http://www.audiomedica.com/oncology/san-antonio-bc-2005/non-anthracyline-regimen-may-be-ok-for-patients-with-early-breast-cancer-taking-trastuzumab-herceptin/</link>
		<comments>http://www.audiomedica.com/oncology/san-antonio-bc-2005/non-anthracyline-regimen-may-be-ok-for-patients-with-early-breast-cancer-taking-trastuzumab-herceptin/#comments</comments>
		<pubDate>Sun, 11 Dec 2005 12:22:59 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[San Antonio BC 2005]]></category>

		<category><![CDATA[chemotherapy]]></category>

		<category><![CDATA[findings]]></category>

		<category><![CDATA[patient]]></category>

		<category><![CDATA[trial]]></category>

		<guid isPermaLink="false">http://audiomedica.com/wp/?p=89</guid>
		<description><![CDATA[<br/>Dennis Slamon, UCLA School of Medicine, Los Angeles
It may be reasonable to replace the anthracycline component of adjuvant chemotherapy with carboplatin in HER-2 positive patients with early breast cancer - provided agents such as docetaxel and trastuzumab are also included, according to the findings of the BCIRG 006 trial reported at the San Antonio Breast [...]]]></description>
			<content:encoded><![CDATA[<br/><p><strong>Dennis Slamon, UCLA School of Medicine, Los Angeles</strong><br />
It may be reasonable to replace the anthracycline component of adjuvant chemotherapy with carboplatin in HER-2 positive patients with early breast cancer - provided agents such as docetaxel and trastuzumab are also included, according to the findings of the BCIRG 006 trial reported at the San Antonio Breast Cancer Symposium.<br />
COMMENT: <strong>Norman Wolmark</strong>, NSABP foundation, Pittsburg<br />
<!-- hide = "Make this available only to subscribers" userlevel=6 --><br />
</p>
<p><!--/hide--><br />
<a href="http://www.audiomedica.com/?page_id=55">Click here for all the interviews from San Antonio Breast Cancer Symposium 2005</a></p>
]]></content:encoded>
			<wfw:commentRss>http://www.audiomedica.com/oncology/san-antonio-bc-2005/non-anthracyline-regimen-may-be-ok-for-patients-with-early-breast-cancer-taking-trastuzumab-herceptin/feed/</wfw:commentRss>
<enclosure url="http://www.audiomedica.com/podcasting/ajo_14.1/01.dennis_slamon.mp3" length="5676432" type="audio/mpeg" />
		</item>
	</channel>
</rss>
